Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth
GlaxoSmithKline Consumer Healthcare, the maker of leading sensitive toothpaste brand Sensodyne, today announced a breakthrough in dental care with the launch of new Sensodyne Re...
Read more -
David Redfern appointed as new Chairman of ViiV Healthcare
GlaxoSmithKline (GSK), ViiV Healthcare, and Pfizer today announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1st Apr...
Read more -
GSK European regulatory update on Pandemrix™ (1)
CHMP concludes that data are insufficient to establish a causal relationship between Pandemrix and narcolepsy.
Read more -
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism
GlaxoSmithKline (GSK) announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme. Kenya is the first African country to receive pneu...
Read more -
GlaxoSmithKline moving to new building at Philadelphia Navy Yard
GlaxoSmithKline (NYSE:GSK), a leading worldwide research-based pharmaceutical company, and Liberty Property Trust (NYSE:LRY) today announced that GSK has signed a 15.5-year leas...
Read more -
GSK revises US Avandia label to include new restrictions on use
GlaxoSmithKline (GSK) today announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines (Avandia, Avandamet; and Avandaryl) to ...
Read more -
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication of the BLISS-52 study of Benlysta (belimumab) in autoantibody-positive patients...
Read more -
GSK results announcement for the fourth quarter
Strategic progress drives positive underlying sales growth*,increasing pipeline potential and improved cash generation. Increased dividend and new long-term share buy-back pr...
Read more -
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD
GSK and Theravance, Inc. today announced major milestones in two clinical development programmes focused on new treatments for patients with COPD, a leading cause of chronic ill...
Read more -
GSK announces the sale of its entire shareholding in Quest Diagnostics
GlaxoSmithKline plc (GSK) announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (Quest).
Read more -
Update on Pandemrix™ and interim Finnish report on narcolepsy
GSK is aware of today's interim report by the Finnish National narcolepsy committee on their investigation into reported cases of narcolepsy in Finland.
Read more -
GSK and Actelion discontinue clinical development of almorexant
GlaxoSmithKline (GSK) and Actelion Ltd (SIX: ATLN) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has be...
Read more -
GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication
GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug App...
Read more -
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma
GlaxoSmithKline (GSK) announced today the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation. The studies will separatel...
Read more -
Regulatory update - GSK and Valeant receive positive opinion in Europe from the CHMP for Trobalt (retigabine)
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) announced today that the European Medicines Agency's Committee for Medicinal Products for...
Read more -
GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968 (`968), in ambulant bo...
Read more -
GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza
GlaxoSmithKline (GSK) announced today that the first patient has received treatment in a pivotal Phase III study of hospitalised patients with influenza which compares intraveno...
Read more -
GlaxoSmithKline announces Q4 2010 legal charge
GlaxoSmithKline (GSK) today announces that it expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion) (equating to an after tax cost of £1...
Read more -
GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK’786, formerly Traficet-EN™, for the treatment of Crohn’s disease
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing...
Read more -
GlaxoSmithKline and DENTSPLY International sign global agreement to create a portfolio of co-branded professional oral care products
GlaxoSmithKline (GSK) and DENTSPLY International, a global leader in professional dental products, today announced that they have entered into an agreement to create a portfolio...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
